Ultragenyx (RARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ultragenyx (RARE) has a cash flow conversion efficiency ratio of 0.342x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-97.00 Million) by net assets ($-284.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Ultragenyx for the company's overall valuation and market capitalisation.
Ultragenyx - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Ultragenyx's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ultragenyx Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultragenyx ranked by their cash flow conversion efficiency. Explore earnings quality score of Ultragenyx to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyient Limited
NSE:CYIENT
|
0.071x |
|
HIAG Immobilien Holding AG
SW:HIAG
|
0.015x |
|
REDOX Ltd
AU:RDX
|
0.066x |
|
ASK AUTOMOTIVE LIMITED
NSE:ASKAUTOLTD
|
0.083x |
|
E2E Networks Limited
NSE:E2E
|
0.020x |
|
TianJin 712 Communication & Broadcasting Co Ltd
SHG:603712
|
-0.055x |
|
Dominos PIZZA Enterprises Ltd
AU:DMP
|
0.148x |
|
ATAI LIFE SCIENCES BV EO1
F:9VC
|
N/A |
Annual Cash Flow Conversion Efficiency for Ultragenyx (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ultragenyx from 2011 to 2025. View RARE stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-73.00 Million | $-466.00 Million | 6.384x | +504.26% |
| 2024-12-31 | $262.30 Million | $-414.19 Million | -1.579x | +8.40% |
| 2023-12-31 | $275.41 Million | $-474.81 Million | -1.724x | -59.72% |
| 2022-12-31 | $352.49 Million | $-380.46 Million | -1.079x | -194.00% |
| 2021-12-31 | $922.56 Million | $-338.69 Million | -0.367x | -220.53% |
| 2020-12-31 | $1.15 Billion | $-132.22 Million | -0.115x | +78.32% |
| 2019-12-31 | $653.76 Million | $-345.38 Million | -0.528x | -10.71% |
| 2018-12-31 | $608.91 Million | $-290.57 Million | -0.477x | +27.92% |
| 2017-12-31 | $383.45 Million | $-253.84 Million | -0.662x | -94.92% |
| 2016-12-31 | $473.97 Million | $-160.97 Million | -0.340x | -70.20% |
| 2015-12-31 | $531.09 Million | $-105.98 Million | -0.200x | +17.32% |
| 2014-12-31 | $184.94 Million | $-44.63 Million | -0.241x | +61.24% |
| 2013-12-31 | $50.11 Million | $-31.20 Million | -0.623x | -319.98% |
| 2012-12-31 | $84.34 Million | $-12.50 Million | -0.148x | +72.91% |
| 2011-12-31 | $10.64 Million | $-5.83 Million | -0.547x | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more